Next Article in Journal
Genome-Wide Dissection of the CRF Gene Family in Brassica napus Indicates that BnaCRF8s Specifically Regulate Root Architecture and Phosphate Homeostasis against Phosphate Fluctuation in Plants
Next Article in Special Issue
Identification of Selective Novel Hits against Plasmodium falciparum Prolyl tRNA Synthetase Active Site and a Predicted Allosteric Site Using In Silico Approaches
Previous Article in Journal
Targeted Delivery of Iron Oxide Nanoparticle-Loaded Human Embryonic Stem Cell-Derived Spherical Neural Masses for Treating Intracerebral Hemorrhage
Previous Article in Special Issue
Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens
Open AccessArticle

Identification of Inhibitors to Trypanosoma cruzi Sirtuins Based on Compounds Developed to Human Enzymes

Instituto Gonçalo Moniz, FIOCRUZ, Salvador 40296710, BA, Brazil
Departamento de Microbiologia, Universidade de São Paulo-USP, São Paulo 05508900, SP, Brazil
Rome Center for Molecular Design, Drug Chemistry and Technology Department, Sapienza University of Rome, 00185 Rome, Italy
Drug Chemistry and Technology Department, Sapienza University of Rome, 00185 Rome, Italy
Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04039032, SP, Brazil
Pasteur Institute, Cenci-Bolognetti Foundation, Sapienza University of Rome, 00161 Rome, Italy
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2020, 21(10), 3659;
Received: 18 March 2020 / Revised: 25 April 2020 / Accepted: 26 April 2020 / Published: 22 May 2020
(This article belongs to the Special Issue Biochemistry, Molecular Biology and Druggability of Proteins)
Chagas disease is an illness caused by the protozoan parasite Trypanosoma cruzi, affecting more than 7 million people in the world. Benznidazole and nifurtimox are the only drugs available for treatment and in addition to causing several side effects, are only satisfactory in the acute phase of the disease. Sirtuins are NAD+-dependent deacetylases involved in several biological processes, which have become drug target candidates in various disease settings. T. cruzi presents two sirtuins, one cytosolic (TcSir2rp1) and the latter mitochondrial (TcSir2rp3). Here, we characterized the effects of human sirtuin inhibitors against T. cruzi sirtuins as an initial approach to develop specific parasite inhibitors. We found that, of 33 compounds tested, two inhibited TcSir2rp1 (15 and 17), while other five inhibited TcSir2rp3 (8, 12, 13, 30, and 32), indicating that specific inhibitors can be devised for each one of the enzymes. Furthermore, all inhibiting compounds prevented parasite proliferation in cultured mammalian cells. When combining the most effective inhibitors with benznidazole at least two compounds, 17 and 32, demonstrated synergistic effects. Altogether, these results support the importance of exploring T. cruzi sirtuins as drug targets and provide key elements to develop specific inhibitors for these enzymes as potential targets for Chagas disease treatment. View Full-Text
Keywords: sirtuins; Trypanosoma cruzi; sirtuin inhibitors; deacetylation sirtuins; Trypanosoma cruzi; sirtuin inhibitors; deacetylation
Show Figures

Figure 1

MDPI and ACS Style

Matutino Bastos, T.; Botelho Pereira Soares, M.; Haddad Franco, C.; Alcântara, L.; Antonini, L.; Sabatino, M.; Mautone, N.; Holanda Freitas-Junior, L.; Moraes, C.B.; Ragno, R.; Rotili, D.; Schenkman, S.; Mai, A.; Silvio Moretti, N. Identification of Inhibitors to Trypanosoma cruzi Sirtuins Based on Compounds Developed to Human Enzymes. Int. J. Mol. Sci. 2020, 21, 3659.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop